Added to YB: 2026-06-15
Pitch date: 2026-06-10
LLY [neutral]
Eli Lilly and Company
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Market Cap
$1.0T
Pitch Price
N/A
Price Target
N/A
Dividend
0.61%
EV/EBITDA
28.77
P/E
40.25
EV/Sales
14.51
Sector
Pharmaceuticals
Category
growth
GS Healthcare Conference – Recap (Day 2 – Part 2) - Eli Lilly and Company
LLY (overview): At $1,181, top-tier healthcare growth story. Mgmt sees obesity in early innings, demand eventually billions of patients. Retatrutide leads: up to 28.3% weight loss at 80wks, >30% in continuers; 4mg dose ~19%. Views obesity as multi-product mkt. Oral Fundyle, Mounjaro, genetic medicines (Verve 102) build future engines.
Read full article (1 min)